← Leaderboards
Midori Kato-Maeda
University Of California, San Francisco
$4,054,180
Attributed
$6,165,723
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $742.5K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,165,723 · 3
By mechanism
R01$6,165,723 · 3
Top collaborators
- Adithya Cattamanchi5 shared
- Swomitra K Mohanty1 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- John Zapata Metcalfe$8,956,853
- Lyudmila Popova$5,221,407
- Pamela May Ling$21,183,506
- Gideon St.helen$5,881,549
- Janice Y. Tsoh$9,696,129
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingMycobacterium TuberculosisDiagnosisMolecularTuberculosisSputumRifampinDrug ResistancePhilippinesPatient-Focused OutcomesCountryEffective TherapyDrug Resistance In TuberculosisResistancePharmaceutical PreparationsIsoniazid ResistanceIsoniazidLaboratoriesFluoroquinolonesIntermediate ResistanceMutationPhenotypeTuberculosis DrugsWorld Health Organization
Grant awards (9)
Innovating anti-tuberculosis drug susceptibility testing with a novel and rapid non-culture based phenotypic test using MPT64 biomarker$632,826
R01 · FY2025 · AI · contact PI
Innovating anti-tuberculosis drug susceptibility testing with a novel and rapid non-culture based phenotypic test using MPT64 biomarker$633,020
R01 · FY2024 · AI · contact PI
Innovating anti-tuberculosis drug susceptibility testing with a novel and rapid non-culture based phenotypic test using MPT64 biomarker$676,791
R01 · FY2023 · AI · contact PI
Evaluation of a novel breath sensor for rapid, low-cost diagnosis of tuberculosis in children$646,982
R01 · FY2021 · HL · contact PI
Improving the molecular diagnosis of drug resistant tuberculosis$696,601
R01 · FY2020 · AI · contact PI
Improving the molecular diagnosis of drug resistant tuberculosis$742,543
R01 · FY2019 · AI · contact PI
Improving the molecular diagnosis of drug resistant tuberculosis$696,346
R01 · FY2018 · AI · contact PI
Improving the molecular diagnosis of drug resistant tuberculosis$709,614
R01 · FY2017 · AI · contact PI
Improving the molecular diagnosis of drug resistant tuberculosis$731,000
R01 · FY2016 · AI · contact PI